Cancer phenomics:: RET and PTEN as illustrative models

被引：178

作者：

Zbuk, Kevin M.

Eng, Charis

机构：

[1] Cleveland Clin Fdn, Genom Med Inst, Cleveland, OH 44195 USA

[2] Cleveland Clin Fdn, Lerner Res Inst, Cleveland, OH 44195 USA

[3] Cleveland Clin Fdn, Taussig Canc Ctr, Cleveland, OH 44195 USA

[4] Case Western Reserve Univ, Sch Med, Dept Genet, Cleveland, OH 44106 USA

[5] Case Western Reserve Univ, Sch Med, Case Comprehens Canc Ctr, Cleveland, OH 44106 USA

来源：

NATURE REVIEWS CANCER | 2007年 / 7卷 / 01期

基金：

美国国家卫生研究院;

关键词：

D O I：

10.1038/nrc2037

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

Cancer phenomics, the systematic acquisition and objective documentation of host and/or somatic cancer phenotypic data at many levels, is a young field compared with other molecular-based 'omics'. Two relatively advanced phenomic paradigms are associated with phosphatase and tensin homologue (PTEN) and rearranged during transfection (RET), genes that are associated with cancer predisposition syndromes in addition to developmental disorders. The phenomic characterization of PTEN and RET underscores the importance of incorporating robust phenomics into the host 'omic' profile, and shows that the evolution of phenomics will be crucial to the advancement of personalized medicine.

引用

页码：35 / 45

页数：11

共 126 条

[1]

Differential expression of novel naturally occurring splice variants of PTEN and their functional consequences in Cowden syndrome and sporadic breast cancer [J].

Agrawal, S ;

Eng, C .

HUMAN MOLECULAR GENETICS, 2006, 15 (05) :777-787

[2]

Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history:: A combined analysis of 22 studies [J].

Antoniou, A ;

Pharoah, PDP ;

Narod, S ;

Risch, HA ;

Eyfjord, JE ;

Hopper, JL ;

Loman, N ;

Olsson, H ;

Johannsson, O ;

Borg, Å ;

Pasini, B ;

Radice, P ;

Manoukian, S ;

Eccles, DM ;

Tang, N ;

Olah, E ;

Anton-Culver, H ;

Warner, E ;

Lubinski, J ;

Gronwald, J ;

Gorski, B ;

Tulinius, H ;

Thorlacius, S ;

Eerola, H ;

Nevanlinna, H ;

Syrjäkoski, K ;

Kallioniemi, OP ;

Thompson, D ;

Evans, C ;

Peto, J ;

Lalloo, F ;

Evans, DG ;

Easton, DF .

AMERICAN JOURNAL OF HUMAN GENETICS, 2003, 72 (05) :1117-1130

[3]

RET receptor signaling: Dysfunction in thyroid cancer and Hirschsprung's disease [J].

Asai, N ;

Jijiwa, M ;

Enomoto, A ;

Kawai, K ;

Maeda, K ;

Ichiahara, M ;

Murakumo, Y ;

Takahashi, M .

PATHOLOGY INTERNATIONAL, 2006, 56 (04) :164-172

[4]

ASAI N, 1995, MOL CELL BIOL, V15, P1613

[5]

DIVERSITY OF RET PROTOONCOGENE MUTATIONS IN FAMILIAL AND SPORADIC HIRSCHSPRUNG DISEASE [J].

ATTIE, T ;

PELET, A ;

EDERY, P ;

ENG, C ;

MULLIGAN, LM ;

AMIEL, J ;

BOUTRAND, L ;

BELDJORD, C ;

NIHOULFEKETE, C ;

MUNNICH, A ;

PONDER, BAJ ;

LYONNET, S .

HUMAN MOLECULAR GENETICS, 1995, 4 (08) :1381-1386

[6]

Lack of PTEN expression in endometrial intraepithelial neoplasia is correlated with cancer progression [J].

Baak, JPA ;

van Diermen, B ;

Steinbakk, A ;

Janssen, E ;

Skaland, I ;

Mutter, GL ;

Fiane, B ;

Lovslett, K .

HUMAN PATHOLOGY, 2005, 36 (05) :555-561

[7]

Potent mitogenicity of the RET/PTC3 oncogene correlates with its prevalence in tall-cell variant of papillary thyroid carcinoma [J].

Basolo, F ;

Giannini, R ;

Monaco, C ;

Melillo, RM ;

Carlomagno, F ;

Pancrazi, M ;

Salvatore, G ;

Chiappetta, G ;

Pacini, F ;

Elisei, R ;

Miccoli, P ;

Pinchera, A ;

Fusco, A ;

Santoro, M .

AMERICAN JOURNAL OF PATHOLOGY, 2002, 160 (01) :247-254

[8]

Clinical and genetic characteristics of patients with neurofibromatosis type 1 and pheochromocytoma [J].

Bausch, Birke ;

Borozdin, Wiktor ;

Neumann, Hartmut P. H. .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (25) :2729-2731

[9]

Bonneau D, 2000, HUM MUTAT, V16, P109, DOI 10.1002/1098-1004(200008)16:2<109::AID-HUMU3>3.0.CO

[10]

2-0

← 1 2 3 4 5 6 7 8 9 10 →